ALBO News and Press, Albireo Pharma Inc. From 09/08/20

-Highly statistically significant reductions in both pruritus and serum bile acids- -Well tolerated with very low incidence of diarrhea- -Similar efficacy in children with PFIC1 or PFIC2- -Pivotal trial results substantiate potential for odevixibat to be first drug for PFIC pa...

Thinly traded micro cap Albireo Pharma (NASDAQ: ALBO ) perks up  10%  premarket on light volume ahead of this morning's conference call (8:30 am ET) to discuss topline results from a Phase 3 clinical trial, PEDFIC 1 , evaluating lead candidate odevixibat in patients with a rar...

BOSTON, Sept. 07, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that topline results from the PEDFIC 1 Phase 3 clinical trial evaluating the efficacy and safet...

The following slide deck was published by Albireo Pharma, Inc. in conjunction with this Read more ...

Thinly traded micro cap Albireo Pharma (NASDAQ: ALBO ) is down  12%  after hours on light volume in reaction to topline results from a Phase 2 clinical trial evaluating constipation med elobixibat for the treatment of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic ...

‒ Achieved primary endpoint ‒ ‒ Unremarkable results in key NASH measures ‒ ‒ Company discontinuing further development ‒ BOSTON, Aug. 18, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver ...

Albireo looks robust after providing corporate updates Albireo Pharma Inc. (ALBO) announced its corporate updates while announcing its financial numbers for the second quarter of the year. The company also reported the impact of COVID-19 outbreak on its operations. Albireo also announced...

Albireo Pharma, Inc. (ALBO) Q2 2020 Earnings Conference Call August 06, 2020 10:00 AM ET Company Participants Paul Arndt - LifeSci Advisors, IR Ron Cooper - President and CEO Pat Horn - CMO Pamela Stephenson - CCO Simon Harford - CFO Conference Call Participants Yasmeen...

Heading into a Q2 earnings call yesterday, Baird was looking to Albireo Pharma (NASDAQ: ALBO ) to provide visibility into its PEDFIC 1 Phase 3 trial - with odevixibat in progressive familiar intrahepatic cholestasis (PFIC) - for which it recently achieved its latest patient visit of a plan...

Image source: The Motley Fool. Albireo Pharma, Inc.   (NASDAQ: ALBO) Q2 2020 Earnings Call Aug 7, 2020 , 10:00 p.m. ET Operator Continue reading